This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Satagopan, J. M. Articles by Begg, C. B. Search for Related Content PubMed PubMed Citation Articles by Satagopan, J. M. Articles by Begg, C. B.

The Lifetime Risks of Breast Cancer in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations

Memorial Sloan-Kettering Cancer Center, New York, New York 10021 [J. M. S., K. O., M. E. R., C. B. B.]; Sir Mortimer B. Davis-Jewish General Hospital, McGill University, Montreal, Quebec, Canada H3A 2T5 [W. F., S. E. K.]; National Cancer Institute, Bethesda, MD 20892 [S. W.]; Mount Sinai School of Medicine, New York, New York 10029 [C. M. E.]; and Medical College of Virginia at Virginia, Commonwealth University, Richmond, Virginia 23284 [S. E. K.]

Several studies using families with multiple occurrences of breast cancer have provided evidence for a very high lifetime penetrance in carriers of BRCA1 or BRCA2 mutations. However, there are reasons to suspect that the estimates of penetrance from studies of cancer families may be inflated. Access to the genotypes of incident cases of breast cancer in three hospitals and from a large series of unaffected survey participants provided the basis for direct estimation of the age-specific relative risks attributable to these mutations, and the resulting lifetime penetrance, without any reference to familial aggregation of cancer. Cases were identified from incident series of Jewish patients treated for primary breast cancer at the three hospitals. Control data were obtained from the large series of Jewish women recruited in the Washington, D.C., area by investigators at the National Cancer Institute and limited to 3434 women with no previous history of breast or ovarian cancer. All subjects were genotyped for the three mutations that are relatively common in Ashkenazi Jews, namely 185delAG and 5382 insC in BRCA1 and 6174delT in BRCA2. For BRCA1, the relative risks of breast cancer were estimated to be 21.6 in women under 40 years of age, 9.6 in women 40–49 years of age, and 7.6 in women 50 years of age. On the basis of these estimates, the penetrance of breast cancer at age 70 among BRCA1 mutation carriers is estimated to be 46% (95% confidence, 31%–80%) rising to 59% (95% confidence, 40%–93%) at age 80. For BRCA2, the relative risks in the same three age categories were estimated to be 3.3, 3.3, and 4.6, respectively, resulting in a penetrance at age 70 of 26% (95% confidence, 14%–50%) rising to 38% (95% confidence, 20%–68%) at age 80. The lifetime risk of breast cancer in Jewish women who are mutation carriers estimated via this approach is substantially lower than the reported lifetime risks estimated using multiple-case families. The risks appear to be different for carriers of BRCA1 and BRCA2 mutations.

This article has been cited by other articles:

				R. L. Milne, A. Osorio, T. R. y Cajal, A. Vega, G. Llort, M. de la Hoya, O. Diez, M. C. Alonso, C. Lazaro, I. Blanco, et al. The Average Cumulative Risks of Breast and Ovarian Cancer for Carriers of Mutations in BRCA1 and BRCA2 Attending Genetic Counseling Units in Spain Clin. Cancer Res., May 1, 2008; 14(9): 2861 - 2869. [Abstract] [Full Text] [PDF]

				J. Yu, A. Park, E. Morris, L. Liberman, P. I. Borgen, and T. A. King MRI Screening in a Clinic Population with a Family History of Breast Cancer Ann. Surg. Oncol., February 1, 2008; 15(2): 452 - 461. [Abstract] [Full Text] [PDF]

				K. L. Smith, M. Adank, N. Kauff, K. Lafaro, J. Boyd, J. B. Lee, C. Hudis, K. Offit, and M. Robson BRCA Mutations in Women with Ductal Carcinoma In situ Clin. Cancer Res., July 15, 2007; 13(14): 4306 - 4310. [Abstract] [Full Text] [PDF]

				J. N. Weitzel, V. I. Lagos, C. A. Cullinane, P. J. Gambol, J. O. Culver, K. R. Blazer, M. R. Palomares, K. J. Lowstuter, and D. J. MacDonald Limited Family Structure and BRCA Gene Mutation Status in Single Cases of Breast Cancer JAMA, June 20, 2007; 297(23): 2587 - 2595. [Abstract] [Full Text] [PDF]

				S. Chen and G. Parmigiani Meta-Analysis of BRCA1 and BRCA2 Penetrance J. Clin. Oncol., April 10, 2007; 25(11): 1329 - 1333. [Abstract] [Full Text] [PDF]

				E. R. Port, A. Park, P. I. Borgen, E. Morris, and L. L. Montgomery Results of MRI Screening for Breast Cancer in High-Risk Patients with LCIS and Atypical Hyperplasia Ann. Surg. Oncol., March 1, 2007; 14(3): 1051 - 1057. [Abstract] [Full Text] [PDF]

				A. Jakubowska, J. Gronwald, J. Menkiszak, B. Gorski, T. Huzarski, T. Byrski, L. Edler, J. Lubinski, R. J. Scott, and U. Hamann The RAD51 135 G>C Polymorphism Modifies Breast Cancer and Ovarian Cancer Risk in Polish BRCA1 Mutation Carriers Cancer Epidemiol. Biomarkers Prev., February 1, 2007; 16(2): 270 - 275. [Abstract] [Full Text] [PDF]

				K. Offit BRCA Mutation Frequency and Penetrance: New Data, Old Debate J Natl Cancer Inst, December 6, 2006; 98(23): 1675 - 1677. [Full Text] [PDF]

				H. A. Risch, J. R. McLaughlin, D. E. C. Cole, B. Rosen, L. Bradley, I. Fan, J. Tang, S. Li, S. Zhang, P. A. Shaw, et al. Population BRCA1 and BRCA2 Mutation Frequencies and Cancer Penetrances: A Kin-Cohort Study in Ontario, Canada J Natl Cancer Inst, December 6, 2006; 98(23): 1694 - 1706. [Abstract] [Full Text] [PDF]

				S. Colilla, P. W. Kantoff, S. L. Neuhausen, A. K. Godwin, M. B. Daly, S. A. Narod, J. E. Garber, H. T. Lynch, M. Brown, B. L. Weber, et al. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers Carcinogenesis, March 1, 2006; 27(3): 599 - 605. [Abstract] [Full Text] [PDF]

				S. Chen, E. S. Iversen, T. Friebel, D. Finkelstein, B. L. Weber, A. Eisen, L. E. Peterson, J. M. Schildkraut, C. Isaacs, B. N. Peshkin, et al. Characterization of BRCA1 and BRCA2 Mutations in a Large United States Sample J. Clin. Oncol., February 20, 2006; 24(6): 863 - 871. [Abstract] [Full Text] [PDF]

				J. L. Kramer, I. A. Velazquez, B. E. Chen, P. S. Rosenberg, J. P. Struewing, and M. H. Greene Prophylactic Oophorectomy Reduces Breast Cancer Penetrance During Prospective, Long-Term Follow-Up of BRCA1 Mutation Carriers J. Clin. Oncol., December 1, 2005; 23(34): 8629 - 8635. [Abstract] [Full Text] [PDF]

				C. B. Begg, I. Orlow, A. J. Hummer, B. K. Armstrong, A. Kricker, L. D. Marrett, R. C. Millikan, S. B. Gruber, H. Anton-Culver, R. Zanetti, et al. Lifetime Risk of Melanoma in CDKN2A Mutation Carriers in a Population-Based Sample J Natl Cancer Inst, October 19, 2005; 97(20): 1507 - 1515. [Abstract] [Full Text] [PDF]

				U.S. Preventive Services Task Force* Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Recommendation Statement Ann Intern Med, September 6, 2005; 143(5): 355 - 361. [Abstract] [Full Text] [PDF]

				H. D. Nelson, L. H. Huffman, R. Fu, and E. L. Harris Genetic Risk Assessment and BRCA Mutation Testing for Breast and Ovarian Cancer Susceptibility: Systematic Evidence Review for the U.S. Preventive Services Task Force Ann Intern Med, September 6, 2005; 143(5): 362 - 379. [Abstract] [Full Text] [PDF]

				C J van Asperen, R M Brohet, E J Meijers-Heijboer, N Hoogerbrugge, S Verhoef, H F A Vasen, M G E M Ausems, F H Menko, E B Gomez Garcia, J G M Klijn, et al. Cancer risks in BRCA2 families: estimates for sites other than breast and ovary J. Med. Genet., September 1, 2005; 42(9): 711 - 719. [Abstract] [Full Text] [PDF]

				A C Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, H Olsson, O Johannsson, A Borg, B Pasini, et al. Breast and ovarian cancer risks to carriers of the BRCA1 5382insC and 185delAG and BRCA2 6174delT mutations: a combined analysis of 22 population based studies J. Med. Genet., July 1, 2005; 42(7): 602 - 603. [Abstract] [Full Text] [PDF]

				B Leegte, A H van der Hout, A M Deffenbaugh, M K Bakker, I M Mulder, A ten Berge, E P Leenders, J Wesseling, J de Hullu, N Hoogerbrugge, et al. Phenotypic expression of double heterozygosity for BRCA1 and BRCA2 germline mutations J. Med. Genet., March 1, 2005; 42(3): e20 - e20. [Full Text] [PDF]

				L Hilakivi-Clarke, C Wang, M Kalil, R Riggins, and R G Pestell Nutritional modulation of the cell cycle and breast cancer Endocr. Relat. Cancer, December 1, 2004; 11(4): 603 - 622. [Abstract] [Full Text] [PDF]

				K. Offit, E. Groeger, S. Turner, E. A. Wadsworth, and M. A. Weiser The "Duty to Warn" a Patient's Family Members About Hereditary Disease Risks JAMA, September 22, 2004; 292(12): 1469 - 1473. [Abstract] [Full Text] [PDF]

				V Abkevich, A Zharkikh, A M Deffenbaugh, D Frank, Y Chen, D Shattuck, M H Skolnick, A Gutin, and S V Tavtigian Analysis of missense variation in human BRCA1 in the context of interspecific sequence variation J. Med. Genet., July 1, 2004; 41(7): 492 - 507. [Abstract] [Full Text] [PDF]

				A. Cabanes, M. Wang, S. Olivo, S. DeAssis, J.-A. Gustafsson, G. Khan, and L. Hilakivi-Clarke Prepubertal estradiol and genistein exposures up-regulate BRCA1 mRNA and reduce mammary tumorigenesis Carcinogenesis, May 1, 2004; 25(5): 741 - 748. [Abstract] [Full Text] [PDF]

				T. Kirchhoff, J. M. Satagopan, N. D. Kauff, H. Huang, P. Kolachana, C. Palmer, H. Rapaport, K. Nafa, N. A. Ellis, and K. Offit Frequency of BRCA1 and BRCA2 Mutations in Unselected Ashkenazi Jewish Patients With Colorectal Cancer J Natl Cancer Inst, January 7, 2004; 96(1): 68 - 70. [Abstract] [Full Text] [PDF]

				D. A. Levine, P. A. Argenta, C. J. Yee, D. S. Marshall, N. Olvera, F. Bogomolniy, J. A. Rahaman, M. E. Robson, K. Offit, R. R. Barakat, et al. Fallopian Tube and Primary Peritoneal Carcinomas Associated With BRCA Mutations J. Clin. Oncol., November 15, 2003; 21(22): 4222 - 4227. [Abstract] [Full Text] [PDF]

				M.-C. King, J. H. Marks, and J. B. Mandell Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2 Science, October 24, 2003; 302(5645): 643 - 646. [Abstract] [Full Text] [PDF]

				B. A. Mincey Genetics and the Management of Women at High Risk for Breast Cancer Oncologist, October 1, 2003; 8(5): 466 - 473. [Abstract] [Full Text] [PDF]

				H. M. Klaren, L. J. van't Veer, F. E. van Leeuwen, and M. A. Rookus Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation J Natl Cancer Inst, July 2, 2003; 95(13): 941 - 947. [Full Text] [PDF]

				M. R. Andersen, R. Smith, H. Meischke, D. Bowen, and N. Urban Breast Cancer Worry and Mammography Use by Women with and without a Family History in a Population-based Sample Cancer Epidemiol. Biomarkers Prev., April 1, 2003; 12(4): 314 - 320. [Abstract] [Full Text] [PDF]

				R. Dalpe, L. Bouchard, A.-J. Houle, and L. Bedard Watching the Race to Find the Breast Cancer Genes Science Technology Human Values, April 1, 2003; 28(2): 187 - 216. [Abstract] [PDF]

				A. S. Whittemore and G. Gong Re: On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance J Natl Cancer Inst, January 1, 2003; 95(1): 76 - 77. [Full Text] [PDF]

				W. Burke Genetic Testing N. Engl. J. Med., December 5, 2002; 347(23): 1867 - 1875. [Full Text] [PDF]

				D. H. Roukos, N. J. Agnanti, E. Paraskevaidis, and A. M. Kappas Approaching the Dilemma Between Prophylactic Bilateral Mastectomy or Oophorectomy for Breast and Ovarian Cancer Prevention in Carriers of BRCA1 or BRCA2 Mutations Ann. Surg. Oncol., December 1, 2002; 9(10): 941 - 943. [Full Text] [PDF]

				J. M. Satagopan, J. Boyd, N. D. Kauff, M. Robson, L. Scheuer, S. Narod, and K. Offit Ovarian Cancer Risk in Ashkenazi Jewish Carriers of BRCA1 and BRCA2 Mutations Clin. Cancer Res., December 1, 2002; 8(12): 3776 - 3781. [Abstract] [Full Text] [PDF]

				D. Thompson, D. F. Easton, and the Breast Cancer Linkage Consortium Cancer Incidence in BRCA1 Mutation Carriers J Natl Cancer Inst, September 18, 2002; 94(18): 1358 - 1365. [Abstract] [Full Text] [PDF]

				M. S. Brose, T. R. Rebbeck, K. A. Calzone, J. E. Stopfer, K. L. Nathanson, and B. L. Weber Cancer Risk Estimates for BRCA1 Mutation Carriers Identified in a Risk Evaluation Program J Natl Cancer Inst, September 18, 2002; 94(18): 1365 - 1372. [Abstract] [Full Text] [PDF]

				W. Burke and M. A. Austin Genetic Risk in Context: Calculating the Penetrance of BRCA1 and BRCA2 Mutations J Natl Cancer Inst, August 21, 2002; 94(16): 1185 - 1187. [Full Text] [PDF]

				C. B. Begg On the Use of Familial Aggregation in Population-Based Case Probands for Calculating Penetrance J Natl Cancer Inst, August 21, 2002; 94(16): 1221 - 1226. [Abstract] [Full Text] [PDF]

				W D Foulkes, J-S Brunet, N Wong, J Goffin, and P O Chappuis Change in the penetrance of founder BRCA1/2 mutations? A retrospective cohort study J. Med. Genet., June 1, 2002; 39(6): 407 - 409. [Full Text] [PDF]

				N. D. Kauff, J. M. Satagopan, M. E. Robson, L. Scheuer, M. Hensley, C. A. Hudis, N. A. Ellis, J. Boyd, P. I. Borgen, R. R. Barakat, et al. Risk-Reducing Salpingo-oophorectomy in Women with a BRCA1 or BRCA2 Mutation N. Engl. J. Med., May 23, 2002; 346(21): 1609 - 1615. [Abstract] [Full Text] [PDF]

				K. L. Nathanson, Y. Y. Shugart, R. Omaruddin, C. Szabo, D. Goldgar, T. R. Rebbeck, and B. L. Weber CGH-targeted linkage analysis reveals a possible BRCA1 modifier locus on chromosome 5q Hum. Mol. Genet., May 16, 2002; 11(11): 1327 - 1332. [Abstract] [Full Text] [PDF]

				D. Thompson and D. Easton Variation in BRCA1 Cancer Risks by Mutation Position Cancer Epidemiol. Biomarkers Prev., April 1, 2002; 11(4): 329 - 336. [Abstract] [Full Text] [PDF]

				H. A. Shih, F. J. Couch, K. L. Nathanson, M. A. Blackwood, T. R. Rebbeck, K. A. Armstrong, K. Calzone, J. Stopfer, S. Seal, M. R. Stratton, et al. BRCA1 and BRCA2 Mutation Frequency in Women Evaluated in a Breast Cancer Risk Evaluation Clinic J. Clin. Oncol., February 15, 2002; 20(4): 994 - 999. [Abstract] [Full Text] [PDF]

				S. Narod, K. Offit, M. Robson, D. Schrag, T. Riggs, M. J. Stoutjesdijk, J. O. Barentsz, J. G.M. Klijn, and H. Meijers-Heijboer Prophylactic Mastectomy in Carriers of BRCA Mutations N. Engl. J. Med., November 15, 2001; 345(20): 1498 - 1500. [Full Text] [PDF]